Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.
List of inclusion Criteria:
- Acute hyperuricemia patients(uric acid>8.0 mg/dl) before/during chemotherapy for
List of exclusion Criteria:
- Hypersensitivity to uricases or any of the excipients.
- Known history of hemolytic anemia (G6PD deficiency).
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)
Outcome Time Frame:
24-48 hours after last dose of rasburicase
Sanofi-aventis administrative office Brazil
Brazil: National Health Surveillance Agency
- Tumor Lysis Syndrome